Firstly, thiazolidinediones such as rosiglitazone remain one of the most widely prescribed class of anti-T2DM drugs with over two decades of pharmacovigilance data substantiating their safety profile, while the HDAC inhibitors vorinostat (SAHA) and LBH589 (panobinostat) have received FDA approval for the third-line treatment of primary cutaneous T cell lymphoma and multiple myeloma, respectively [15, 49–51]. The gene discussed is HDAC9; the disease is AL amyloidosis.